Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Total Current Liabilities (2020 - 2025)

RxSight (RXST) has disclosed Total Current Liabilities for 6 consecutive years, with $26.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 1.46% year-over-year to $26.3 million, compared with a TTM value of $26.3 million through Dec 2025, up 1.46%, and an annual FY2025 reading of $26.3 million, up 1.46% over the prior year.
  • Total Current Liabilities was $26.3 million for Q4 2025 at RxSight, up from $22.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $26.3 million in Q4 2025 and bottomed at $9.2 million in Q3 2021.
  • Average Total Current Liabilities over 5 years is $17.8 million, with a median of $18.3 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities decreased 4.51% in 2021, then soared 78.38% in 2022.
  • Year by year, Total Current Liabilities stood at $11.1 million in 2021, then surged by 55.61% to $17.2 million in 2022, then increased by 21.27% to $20.9 million in 2023, then grew by 23.79% to $25.9 million in 2024, then increased by 1.46% to $26.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for RXST at $26.3 million in Q4 2025, $22.3 million in Q3 2025, and $20.4 million in Q2 2025.